REG - Roquefort Theraptcs. - Notice of AGM

Roquefort TherapeuticsAnnouncement

07/06/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220607:nRSG8650Na&default-theme=true

RNS Number : 8650N  Roquefort Therapeutics PLC  07 June 2022

7 June 2022

 

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

Notice of Annual General Meeting

 

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company
focused on early-stage opportunities in the biotechnology sector, has today
posted its Notice of Annual General Meeting to Shareholders. The Annual
General Meeting is scheduled to take place at the offices of Ince Gordon Dadds
LLP, Aldgate Tower, 2 Leman Street, London E1 8QN at 10.00 am on 30 June 2022.

 

The Notice of Annual General Meeting and Forms of Proxy can be downloaded from
the Company's corporate website at
https://www.roquefortplc.com/category/shareholder-documents/
(https://www.roquefortplc.com/category/shareholder-documents/)

 

-Ends-

 

Enquiries:
 Roquefort Therapeutics plc
 Stephen West (Chairman)                    +44 (0)20 3290 9339

 Buchanan (Public Relations)

 Ben Romney / Jamie Hooper / George Beale   +44 (0)20 7466 5000

 Optiva Securities Limited (Broker)
 Christian Dennis                           +44 (0)20 3411 1881

 

For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com (http://www.roquefortplc.com) and @RoquefortTherap on
Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

 

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is a Main Market listed biotech company
developing products through the pre-clinical phase prior to partnering or
selling to big pharma.  The Company is a pre-clinical biotech company
focused on developing first in class Midkine targeting drugs for the treatment
of cancer.

 

Through extensive research resulting in validation through publication in over
1,000 scientific journals, Roquefort Therapeutics has identified the potential
to exploit the broad therapeutic potential of Midkine for a number of clinical
indications of unmet needs. Roquefort Therapeutics holds an exclusive licence
to the largest global IP portfolio on Midkine. The Midkine blocking drug
development markets have significant global market potential (in the
multi-billion dollars). Roquefort Therapeutic's pre-clinical program is
currently underway with an initial focus on cancer.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOASSMFEMEESEDM